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This case describes a 5-month-old male who presented with respiratory distress and superior vena cava
syndrome due to malignant ectomesenchymoma (MEM). Surgical treatment was limited to biopsy
because of the extensive tumor involvement of the heart and great vessels. The patient was treated with
sarcoma-directed chemotherapy. This is the ﬁrst reported case of a primary MEM in the chest as well as
the ﬁrst case of MEM with cardiac invasion. The work up, differential diagnosis, and treatment of this
extremely rare entity are presented.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. Malignant ectomesenchymoma (MEM) is a rare tumor derived
from embryologic tissue known as ectomesenchyme. Composed of
both neuroblasts and mesenchymal elements, MEM can be chal-
lenging to diagnose. Fifty-six cases of MEM have been described in
the literature [1]. We present a 5-month-old male with superior
vena cava (SVC) syndrome because of MEM in the right chest, which
represents the ﬁrst reported case of primary MEM in the thorax.1. Case report
A 5-month-old African American male presented with a
2-month history of increased work of breathing and progressive
facial swelling with bluish discoloration. A chest radiograph
revealed complete opaciﬁcation of his right lung, and he was
referred for further management. Past medical history was notable
only for sensorineural congenital hearing loss. His family and birth
history were unremarkable. Physical exam revealed intercostal
retractions, coarse rhonchi bilaterally, decreased breath sounds
over the right lung ﬁeld and diffuse end-expiratory wheezing.
Laboratory work up was within normal limits.
A computed tomography (CT) of the chest revealed
a 7.5 cm  6.5 cm mass in the right thorax with low-density areas,
suggestive of necrosis (Fig. 1a). The mediastinum was compressedgery, Connecticut Children’s
6106, USA. Tel.: þ1 860 545
-NC-ND license. and shifted to the left; the right lung was atelectatic; and the SVC
was severely compressed without evidence of collaterals. An
echocardiogram demonstrated an SVC gradient of 24 mm Hg. Due
to the extensive vascular involvement leading to mediastinal and
SVC compression, the patient was thought to be unresectable.
He was given empiric chemotherapy with cyclophosphamide
(5 mg/kg/day for 3 days), dexamethasone (0.1 mg/kg/day for
2 days) and vincristine (0.025 mg/kg/day for 1 day). After chemo-
therapy, an echocardiogram revealed that the SVC gradient
improved to 6e8 mm Hg, but was still elevated above the normal
2.5 mm Hg or less.
An open biopsy performed on the second day of the initial
chemotherapy regimen demonstrated serosanguineous ﬂuid,
devoid of malignant cells on cytology, as well as an iridescent,
white lung mass. Hematoxylin and eosin staining of the biopsy
specimens showed nests and sheets of primitive mesenchymal
cells inﬁltrating ﬁbrous tissue, with foci of necrosis; hemorrhage
and mitotic ﬁgures (Fig. 2aec). Based on the immunohistochem-
istry results (Fig. 2def), the most likely diagnosis was pleuro-
pulmonary blastoma (PPB) [2], with fetal lung interstitial tumor
(FLIT) less likely [3]. Metastatic work up included negative cere-
brospinal ﬂuid (CSF) studies, bilateral bone marrow biopsies and
aspirates, abdominal ultrasound, CT of the abdomen, magnetic
resonance imaging/angiogram/venogram (MRI, MRA, MRV) of the
brain and bone scan. Serum alpha fetoprotein (AFP), serum beta
human chorionic gonadotropin (b-HCG) levels, urine vanillyl-
mandelic acid (VMA), and urine homovanillic acid (HVA) were
within the normal range. Chemotherapy was continued with
Fig. 1. Imaging of a mass arising from the right hemithorax. Initial thoracic computed tomography (CT) with contrast demonstrated a large heterogenous mass occupying most of
the right lung. The superior vena cava (SVC) is signiﬁcantly compressed (black arrow). The cardiac silhouette is shifted slightly to the left. The left lung is clear. (b) 2D echocardiogram
obtained after 1 cycle of vincristine, dexamethasone, and cyclophosphamide, 8 cycles of vincristine, doxorubicin, and cyclophosphamide, and 2 cycles of bevacizumab, topotecan,
cyclophosphamide, and vincristine demonstrating extension of the tumor into the left atrium (LA). A 1.6  2.0 cm mass (white arrow) is seen in the LA, along with the larger extra-
cardiac mass. Left ventricle (LV), right atrium (RA) and right ventricle (RV) are marked.
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and cyclophosphamide (36 mg/kg/day) given week 0 and vincris-
tine alone given week 1 (VAC) [4].
Further review of the case revealed features suggestive of a primi-
tive neuroectodermal tumor (cellswith positive immunoreactivity for
S100 and CD56) and rhabdomyosarcoma (cells with positiveFig. 2. Histopathology of a tumor arising from the right lung of an infant. (aec) Hematoxylin
mesenchymal cells inﬁltrating ﬁbrous tissue (b) small round primitive cells and (c) cord
parenchyma, cystic components or neuropil, rosettes, ganglion cells were observed in the
primitive mesenchymal cells within the tumor are positive for (d) desmin and (e) myogenin
contrast, the small round primitive cells within the ﬁbromyxoid stroma were positive for CD
the rhabdomyosarcoma and primitive neuroectodermal tumor components, the most likelyimmunoreactivity fordesminandmyogenin). Basedon thispathology,
the diagnosis ofMEMwasmade and treatmentwas changed to the P6
regimen: vincristine, doxorubicin and cyclophosphamide for cycles
1e3,with an increase indose for each cycle due to his young age to the
goal of 0.067 mg/kg/dose vincristine, 37.5 mg/m2/dose doxorubicin
and70mg/kg/dose cyclophosphamide [5]. SurveillanceCTscansof theand eosin staining of the biopsy specimens depicting (a) nests and sheets of primitive
s of primitive cells within ﬁbromyxoid stroma. No features of normal residual lung
biopsy specimens. (def) immunohistochemistry of the biopsy samples shows that the
, suggestive of rhabdomyosarcoma or, in the lung, pleuropulmonary blastoma (PPB). In
56 (f) and S100 (not shown), suggestive of a primitive neuroectodermal tumor. Due to
diagnosis is malignant ectomesenchymoma.
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mass, stable size, and persistent compression of the SVC, right
pulmonary artery and veins. Resectionwas not a prudent option, even
with cardiopulmonary bypass support. Chemotherapy was continued
and local control deferred until such time as tumor response to
chemotherapy allowed complete resection of the mass.
The patient developed life-threatening Klebsiella sepsis
following the 3rd cycle of P6; therefore, subsequent cycles were
limited to 75% of the goal doses. After completing 8 cycles of the P6
protocol without improvement, treatment was changed to bev-
acizumab, topotecan, cyclophosphamide and vincristine as per the
COG-AEWS0521 protocol [6]. After 2 cycles of this combination, the
tumor progressed and began to invade the left atrium (Fig. 1b). The
chemotherapy regimen was changed to vincristine, irinotecan and
temozolomide (VIT) [7] for 2 cycles, without response. One cycle of
bevacizumab, sorafenib and cyclophosphamide was attempted
before the patient succumbed to his disease at age 16 months.
2. Discussion
Our case represents the ﬁrst reported primary thoracic MEM,
presenting as a chest mass in an infant with SVC syndrome. The
mass was unresectable due to its intimate involvement with the
great vessels of the thorax. The differential diagnosis included
neuroblastoma, lymphoma, FLIT, Ewing’s sarcoma, PPB, and MEM.
The pathology was inconsistent with neuroblastoma, lymphoma,
Ewing’s sarcoma or FLIT. PPB, a rare dysontogenetic neoplasm of
childhood, was the diagnosis initially considered. Given the solid
nature of the tumor in an infant, as well as the histopathological
features, PPBwas ultimately considered to be unlikely. While tumor
cells stained for desmin and myogenin consistent with rhabdo-
myosarcoma, primary rhabdomyosarcoma of the chest is exceed-
ingly rare in infants.
MEM is a rare tumor composed of ganglion cells or neuroblasts
with one or more malignant mesenchymal elements. It derives
from the ectomesenchyme, the embryologic migratory neural crest
tissue that forms the neuroectoderm and mesenchymal tissues.
Information regarding treatment and outcome is available for 40 of
the 56 cases of MEM reported in pediatric patients [1,8e12]. The
mean age at presentation was 4.4 years, with 30% of pediatric cases
presenting before the age of 1 year. MEM has been diagnosed in
patients as young as 10 days old and affects males and females
equally [13]. The tumor’s reported tissue of originwas the head and
neck (16%), abdomen (22%), perineal area (29%), limbs or soft
tissues (9%) and brain (13%) [1,8e12]. Although several cases of
metastatic MEM in the lungs have been described [14], no case of
primary MEM of the intrathoracic structures has been described
[1,8e12]. Symptoms due to MEM are usually attributed to local
pressure from the tumor and clinically insigniﬁcant, however the
location of this tumor led to SVC syndrome.
The neural component of MEM is usually neuroblastoma, but
ganglioneuroblastoma, ganglioneuroma and primitive neural
ectodermal tumor (PNET) have been described. In contrast, the
mesenchymal component is usually rhabdomyosarcoma, but
chondrosarcoma, gliosarcoma and malignant glandular sarcoma
have been observed [15]. In our case, the tumor was composed of
rhabdomyosarcoma with PNET as the neural component. Because
rhabdomyosarcoma is the most common malignant component of
MEM, neoadjuvant or adjuvant chemotherapy commonly is based
on rhabdomyosarcoma therapy.
The main feature predictive of good prognosis in MEM is
resectability; patients who have succumbed to the disease had an
unresectable primary tumor or metastases at the time of diagnosis
[1]. Our patient had no metastases at the time of diagnosis, but the
proximity of the tumor to the patient’s airways and great vesselsprecluded resection. Unfortunately, neither the initial chemo-
therapy nor the salvage regimens decreased the tumor burden
sufﬁciently so that resection could be attempted safely.
3. Conclusion
In conclusion, we describe the ﬁrst reported case of a primary
MEM arising in the thorax, presenting as SVC syndrome in an infant.
The tumor’s invasion of the mediastinal and thoracic structures
made it unresectable, while its limited response to chemotherapy
caused our patient to eventually succumb to his disease.
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